Development of a recombinant human collagen-type III based hemostat.

Area of Science:

• Biomaterials Science
• Hemostasis Research
• Collagen Biology

Background:

• Animal-tissue-derived collagen, primarily type I with some type III, is used in hemostats.
• Type III collagen is known to induce platelet aggregation in vitro, but purification challenges limit in vivo correlation.
• Previous studies suggest type III collagen's role in platelet aggregation.

Purpose of the Study:

• To investigate the hemostatic potential of recombinant human type III collagen.
• To compare the platelet aggregation capabilities of type III collagen with type I collagen.
• To evaluate the performance of type III collagen-based hemostats in a preclinical model.

Main Methods:

• Production of recombinant human type III collagen fibrils.
• In vitro assessment of platelet aggregation induced by type III and bovine type I collagen fibrils.
• Fabrication of three-dimensional collagen matrices.
• Evaluation of hemostatic activity in a rabbit spleen injury model.

Main Results:

• Recombinant human type III collagen fibrils induced greater platelet aggregation in vitro than bovine type I collagen fibrils.
• Three-dimensional matrices of type III collagen exhibited enhanced mechanical integrity and larger surface area.
• Type III collagen-based hemostats demonstrated significantly higher hemostatic activity in vivo compared to commercial type I collagen hemostats.

Conclusions:

• Recombinant human type III collagen possesses superior properties for hemostat applications.
• Type III collagen matrices offer improved structural and functional characteristics for wound management.
• This study validates the potential of type III collagen as a key component in next-generation hemostatic agents.